CPD supplements

Gene therapy: regional assessment comparison

By , , 2020-11-01T15:52:00

AdobeStock_268793304

Axicabtagene ciloleucel (tradename YESCARTA) is an autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets CD19 and is approved for the treatment of aggressive, relapsed or refractory forms of B-cell non-Hodgkins lymphoma (NHL). The active substance is composed of a patient’s cells that have undergone ex vivo modification, which causes ...

 This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.

 

Not a TOPRA member yet? Join our global community before
30 September and get 3 month’s extra membership for only £20.

Join by 30 September to get this exclusive rate.

Five great reasons to become a TOPRA member:

  1. Great savings on our events and training.
  2. Be part of our dynamic international community.
  3. Contribute to the profession.
  4. Grow your skills and knowledge.
  5. Take your career to the next level.

Become a member today!

Have you heard? Why not listen to one of our free podcasts to see what you’re missing?